







ANALYZING THE MORPHOLOGY OF HEMOZOIN IN DRUG RESISTANT 
PLASMODIUM 
& 
 QUANTIFYING THE COMPARTMENTAL KINETICS OF HEMOZOIN 
















A thesis submitted to the Johns Hopkins University in conformity with the requirements 
















©2019 Abeer Sayeed 
All Rights Reserved  
 ii 
ABSTRACT 
Malaria infection by Plasmodium parasites poses a significant public health 
burden globally. During the parasite’s erythrocytic life cycle stages, it produces 
hemozoin, an inert, crystalline by-product of hemoglobin degradation, to avoid oxidative 
stress. This process is essential for parasite survival and is therefore a target for 
antimalarials. In this thesis, we explore the effect of single nucleotide polymorphisms 
(SNPs) in drug resistant parasites on hemozoin morphology. We found that parasites with 
compressed trophozoite stages in a ring-stage artemisinin resistant strain (C580Y) 
harboring a Kelch-13 propeller mutation, produce significantly smaller sized hemozoin 
crystals than the isogenic susceptible strain (CamWT). Smaller sized hemozoin crystals 
were also observed in a chloroquine resistant strain (FCB) as compared to its isogenic 
chloroquine sensitive strain (106/1). We did not observe a significant difference in non-
isogenic drug sensitive and resistant strains, suggesting that a SNP conferring resistance 
may be sufficient to alter hemozoin morphology. From these data we predict that 
parasites may alter their hemozoin nucleation processes as a stress response in order to 
overcome drug pressure. 
Current malarial diagnostics have their limitations and therefore need 
improvement. Hemozoin is being explored as a potential biomarker to be used in malaria 
diagnostics. Therefore, it is essential to understand the kinetics of hemozoin during 
infection and clearance in order to develop appropriate tools to detect malaria infection 
using hemozoin. Additionally, in this thesis, we developed a sensitive luminescence assay 
to quantify hemozoin, with the ultimate goal of being able to detect and quantify 
hemozoin within the RBC and plasma compartments of whole blood. In P. berghei 
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infected white mice, we quantified hemozoin in the livers, spleens, whole blood, RBC, 
and plasma fractions to observe the kinetics of hemozoin during clearance of infection. 
We found that hemozoin is more concentrated in the liver at days 0-4 post treatment, after 
which hemozoin is more concentrated in the spleen. This corresponds to an increase in 
whole blood concentration during days 4-10 post treatment, suggesting that hemozoin is 
transported from the liver to the spleen via whole blood during clearance of infection. We 
were able to quantify hemozoin in both the RBC and plasma fractions of mouse whole 
blood. We observed a higher hemozoin concentration in RBCs during the first 2 days 
post clearance. After day 7 however, there were more quantifiable plasma samples than 
RBC samples. With the exception of 1 sample, we were unable to detect hemozoin in 
either plasma or RBC fraction past day 25 post treatment.  
We were also able to detect and quantify hemozoin in the RBC and plasma 
fractions of infected human patients’ whole blood. Although limited in the number of 
samples, we observed higher hemozoin concentrations in the RBC fraction as compared 
to the plasma, and a rapid decline in concentrations between days 0-2 post treatment. 
These observations reflected what occurred in the mouse model. With more human 
patient samples, we can continue to utilize our sensitive luminescence assay to observe 
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INTRODUCTION 
Malaria is a life-threatening disease for which roughly half of the world’s 
population is at risk. In 2017, there were an estimated 219 million cases of malaria and 
435,000 deaths reported. Over 90% of cases are found in sub-Saharan Africa. High risk 
populations for malaria include pregnant women and children, where over two-thirds of 
malaria deaths occur in children under the age 5 [1].   
Malaria is the clinical manifestation of infection by the Plasmodium parasite. The 
parasite undergoes a complex life cycle in which asexual replication occurs within host 
red blood cells (RBCs). Within host RBCs, the parasite degrades hemoglobin for amino 
acids, a process essential for parasite survival and replication. The heme byproduct is 
crystalized into hemozoin to remove heme from solution chemistry participating in 
oxidative-reduction reactions. A single parasite produces ~1.5 fmol of hemozoin during 
one growth cycle [2]. One human patient with a 1% parasitemia will have 2.4x10
11
 
parasites in their total 6 L volume of whole blood. Therefore, a single patient will 
produce 3.6x10
11
 fmol of hemozoin. Assuming each of the 217 million cases diagnosed 
in 2017 had at least a 1% parasitemia, this would yield roughly 48,000 moles of 
hemozoin or thirty thousand kilograms of heme (616 g/mol) produced from malaria 
infections in 2017.  
Because hemozoin production is an essential part of the Plasmodium life cycle, 
this process is a common drug target for current antimalarials. However, with emerging 
drug resistance, it is important to elucidate the mechanisms of hemozoin production in 
order to understand Plasmodium responses under drug pressure. In this thesis, we seek to 
understand parasite stress response by observing the morphological effect of drug 
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resistance on hemozoin morphology. The chemical and physical properties of hemozoin 
can be exploited to improve upon detection and diagnosis of malaria. Therefore, in this 
thesis we also explore the kinetics of hemozoin in blood throughout the clearance of 
Plasmodium falciparum infection in human patients and Plasmodium berghei infection in 
a mouse model.     
1.1 The asexual life cycle of Plasmodium 
The malaria parasite Plasmodium has a complex life cycle which requires at least 
two hosts for it to successfully propagate within a population, attributing to its 
widespread disease burden. Transmission of the parasite occurs via the female Anopheles 
mosquito. Human infection begins when an infected mosquito takes a bloodmeal from a 
naïve human while depositing Plasmodium sporozoites through its saliva into the dermis. 
From the skin, the sporozoites use gliding motility to migrate towards blood vessels [3]. 
Upon entering the bloodstream, the sporozoites traverse to the liver to invade hepatocytes 
and develop into schizonts. After establishing liver-stage infection over roughly 7-10 
days, merosomes bud from the infected hepatocyte to release merozoites into the blood 
stream [3]. Thus begins the erythrocytic, asexual stages of the parasite life cycle. Upon 
RBC invasion, the parasite begins its 48 hour intra-erythrocytic life cycle by developing 
into a ring structure and beginning to feed on the RBC cytoplasm [3,4]. It then matures 
into a trophozoite, a stage in which hemozoin is detected microscopically, increasing its 
metabolic activity and restructuring the host RBC. Schizogony occurs as repetitive 
nuclear division produces around 20 daughter merozoites which are released from the 
RBC to further invade naïve RBCs. This asexual cycle of invasion, replication, and 
release during the blood stage of infection allows parasite titers to increase to a level 
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within the blood that causes the cyclical fevers typically associated with the symptoms of 
malaria. 
   During asexual replication within the RBC, a small portion of parasites commit to 
sexual development to produce male and female gametocytes, also containing hemozoin. 
Gametocytes sequester in the bone marrow for 11 days to fully mature before they 
emerge into the peripheral circulation of the now infective human host [3]. Plasmodium 
transmission is driven as mosquitoes become infected when picking up gametocytes from 
a vertebrate host during a blood meal. Within the mosquito, the parasite develops from a 
gametocyte in the blood meal to an ookinete, which can traverse the midgut epithelium to 
form an oocyst on the basal lamina of the mosquito midgut. The oocyst, the final 
hemozoin-containing stage, harbors development of motile sporozoites, which upon 
release from the oocyst into the mosquito hemocoel, travel to the salivary glands [5]. 
Once the salivary glands have been invaded with sporozoites, the mosquito is ready to 
infect a naïve vertebrate host with Plasmodium, continuing the parasite’s life cycle and 
the transmission of malaria. 
1.2 Hemoglobin metabolism 
During the erythrocytic stages of the Plasmodium life cycle, the parasite feeds on 
host RBC cytoplasm. More than 95% of RBC cytoplasm consists of hemoglobin, of 
which 60-80% is degraded by the parasite as it matures within the RBC [6]. Amino acids 
derived from hemoglobin metabolism are essential for parasite survival due to its limited 
ability for amino acid synthesis or uptake [7]. By inhibiting hemoglobin proteases within 
the parasite, it has been shown that parasite development is interrupted; therefore, 
hemoglobin metabolism is an important process for parasite maturation [6]. During early 
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ring stages, parasite cytostomes pick up small portions of host cytoplasm through 
micropinocytosis. As the parasite matures into the trophozoite stages, larger volumes of 
cytoplasm are ingested into vesicles which fuse to form a digestive vacuole within the 
parasite [6]. This organelle has an estimated pH of 5.0-5.4 and is maintained by a proton 
gradient which can activate an ATPase pump [8]. The process of hemoglobin degradation 
within the digestive vacuole is ordered and primarily conducted by aspartic and cysteine 
proteases. Aspartic protease plasmepsin I is synthesized during early ring stages but is not 
as abundant as plasmepsin II, which only appears during trophozoite stages [6]. This 
coincides with the observations that hemoglobin metabolism begins during the ring stage, 
but an increase in metabolic activity is attributed to trophozoites when most of the host 
cell cytoplasm is consumed. Plasmepsins I and II initially cleave hemoglobin at the 
highly specific 33Phe-34Leu site, unraveling the tetramer and allowing for further 
cleavage at other sites [9,10]. Inhibiting plasmepsin I activity blocks hemoglobin 
degradation and is lethal to the parasite, whereas plasmepsin II does not seem to be an 
essential protease for parasite survival [6]. A cysteine protease, falcipain, acts on 
hemoglobin after it has been denatured by plasmepsins. Blocking cysteine protease 
activity is detrimental to the parasite as it impairs parasite growth [6]. Figure 1.1  
summarizes the predicted pathway of hemoglobin metabolism to produce amino acids for 
the parasite’s use. 
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Fig. 1.1 Proposed pathway for hemoglobin degradation in P. falciparum.  
Taken from Francis et al. [6] 
 
During the process of hemoglobin degradation, free heme is released in the 
digestive vacuole and oxidized to the ferric state. This oxidation leads to the production 
of reactive oxygen species such as superoxide anions (O2
-
), hydroxyl radicals (OH
•
), and 
hydrogen peroxide (H2O2) [6,11]. Oxidative stress caused by reactive oxygen species can 
damage the parasite digestive vacuole as well as the host cell. Detoxification of heme is 
required by the parasite due its lack of heme oxygenase as to avoid oxidative stress [12]. 
Therefore, the parasite sequesters the free heme released from hemoglobin degradation 
and converts it to an inert crystal in the form of hemozoin [6,12]. 
1.3 Hemozoin formation 
 Although the mechanisms of hemozoin formation have not been completely 
elucidated, several hypotheses have been proposed and disputed. Originally, Slater et al. 
proposed that hemozoin was a polymer formed by a “heme polymerase” enzyme by 
demonstrating that monomeric heme polymerization was dependent on time, heat, and 
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pH [13]. However, the theory of a parasitic enzyme responsible for hemozoin formation 
was later disproved after lack of deactivation by boiling or adding protease was observed, 
therefore concluding that the process was autocatalytic in the presence of hemozoin or -
hematin [14]. Additionally, Sullivan et al. proposed that histidine-rich protein II (HRPII) 
may also be responsible for hemozoin formation [15]. However, later studies showed that 
clones lacking HRPII genes are still able to produce hemozoin, therefore establishing that 
HRP is sufficient but not necessary for hemozoin formation [16,17]. Another protein, 
heme detoxification protein (HDP), has been proposed as being involved in hemozoin 
production due to its higher heme binding affinity than HRPII [18]. Other studies 
suggested the theory of neutral lipids associated with the digestive vacuole promoting 
hemozoin formation [19]. TEM imaging of parasites and subcellular fractionation have 
identified neutral lipid bodies in association with hemozoin in the digestive vacuole [20]. 
There is increasing evidence that these digestive vacuole neutral lipid nanospheres 
accumulate free heme and promote hemozoin formation. Further research is being 
conducted to identify the necessary conditions for hemozoin formation.  
1.4 Hemozoin structure and properties 
Early studies on the structure of hemozoin were conducted in 1987 by Fitch and 
Kanjananggulpan who purified hemozoin and studied its solubility properties to show it 
consisted of ferriprotoporphyrin IX (Fe(III)PPIX), an iron atom surrounded by a 
porphyrin ring structure of four nitrogen atoms, suggesting this structure to be identical to 
-hematin, a synthetic Fe(III)PPIX [12,21]. This was confirmed with X-ray diffraction 
patterns showing that the chemical structure of hemozoin is indeed identical to that of -
hematin [22,23]. In 2000, when the structure of -hematin was deduced, early 
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assumptions of hemozoin as a polymer were invalidated. We now know that hemozoin is 
a crystalline dimer with iron carboxylate bonds to the propionic side chains of the 
porphyrin ring [24]. Hemozoin crystals from mammalian Plasmodium are brick-like 
structures with an average dimension of 100 nm x 100n m x 300-500 nm [25]. When 
compared to hemozoin from other Plasmodium species, hemozoin morphology can differ 
by shape and size [25]. 
Because the structure of hemozoin is similar to that of -hematin as was shown by 
similar IR spectra and X-ray diffraction, certain properties of -hematin reflect those of 
hemozoin. For example, hematin has paramagnetic properties that can be exploited to 
develop hemozoin detection or quantification tools. This property has been previously 
used for separating infected RBCs from uninfected RBCs. The unique optical dichroism 
patterns generated from the crystal structure of hematin can be combined with its 
magnetic properties to develop diagnostic tools. It has also been observed that exposure 
of a parasite to a strong magnetic field can spin hemozoin crystals and potentially disrupt 
hemozoin formation [12] 
1.5 Malaria diagnostics and hemozoin as a biomarker 
An essential component of eliminating malaria worldwide is accurate diagnosis of 
the disease. Due to its nonspecific clinical presentation such as fever and other flu-like 
symptoms, misdiagnosis is possible and can have serious consequences. Nonetheless, 
clinical diagnosis of malaria is commonly used in endemic regions where there is lack of 
access to other diagnostic tools. The current gold standard for malaria diagnosis is 
microscopy. This involves taking a peripheral blood sample to make a blood film on 
which parasites are visualized by Giemsa staining. This method is quick and reliable, and 
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is currently the most efficient way to make a malaria diagnosis in the field. However, 
microscopy has a limit of detection of 50-100 parasites/ul, which is a disadvantage when 
trying to detect subclinical malaria in which low parasite burden exists but does not cause 
clinical symptoms [26]. Therefore, molecular diagnostics, such as detecting parasite 
DNA or RNA using PCR, are a more sensitive method to accurately confirm infection. 
Because the limit of detection for PCR is 0.5-1 parasite/ul, subclinical malaria can also be 
diagnosed [26]. However, PCR is not a practical tool to use in the field due to limiting 
requirements of having an extensive lab setting with trained professionals to perform the 
assay. A third major class of malaria diagnostics includes rapid detection tests (RDTs). 
Although not quantitative like microscopy or PCR, RDTs are simple to use making them 
an excellent candidate for field diagnostics. They only require 10-15ul of blood and 
results are obtained immediately. RDTs rely on parasitic antigens such as aldolase or 
HRPII as a method of detection [26]. However, there is evidence that these antigens can 
linger in peripheral blood after clearance of infection, therefore increasing the possibility 
of false positives by RDT [27]. There is a continuous push to increase the sensitivity of 
the current diagnostic tools used in the field without compromising the accuracy of the 
diagnosis. 
Other innovative methods are being explored to detect malaria infection. This 
includes utilizing the properties of hemozoin to create diagnostic tools. The diverse 
properties of hemozoin allow it to be detected in several different ways. The most 
explored method of hemozoin detection is by using mass spectrometry to identify the 
ionized fragments of heme crystals. Specifically using laser-desorption mass 
spectrometry (LDMS) excitation of hemozoin heme produces ions which acquire kinetic 
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energy proportional to their charge. Ions with different masses have different times-of-
flight (TOF) which are recorded in a spectrum [28]. The parent fragment used to identify 
hemozoin occurs at a unique mass to charge ratio of 616 m/z (the molecular weight of 
heme is 616 Da), with other characteristic fragments occurring at 484, 498, 512, 526, 
557, and 571 m/z [28]. Studies have shown successful detection of hemozoin using 
LDMS both in vitro and in vivo. Non-invasive methods exploiting the excitation 
properties of hemozoin heme are being explored as diagnostic tools [29]. However, 
creating a portable and affordable device to detect hemozoin using mass spec has yet to 
be accomplished. 
The magnetic and birefringent properties of hemozoin are also being used to 
develop novel diagnostic tools to use in the field. Such devices use a magnet to align 
hemozoin such that the crystals block polarized light. The amount of light blocked is 
proportional to the concentration of hemozoin [30]. The sensitivity of magneto-optical 
hemozoin diagnostic tools is 10-40 parasites/ul [29]. This avenue of diagnosis is 
comparatively more sensitive than microscopy diagnosis but still not as sensitive as 
nucleic acid detection. Another diagnostic technique being developed uses laser pulses to 
create hemozoin-generated vapor nanobubbles underneath the skin, avoiding the use of a 
needle to obtain blood [31]. Therefore, there are a variety of methods being explored 
using hemozoin as a diagnostic tool. 
1.6 Kinetics of hemozoin formation 
Up to 95% of heme iron released from hemoglobin degradation is sequestered to 
form hemozoin within the Plasmodium digestive vacuole [32]. This was observed by 
measuring the total iron in parasitized RBCs, isolated trophozoites, and digestive 
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vacuoles. Parasitized RBCs contain the same amount of iron as non-parasitized cells: 
~90-111 fg/cell, indicating that there is no significant loss of iron during parasitic 
invasion of an erythrocyte [32]. Mӧssbauer spectroscopy of trophozoites only identified 
spectra of iron species identical to that of -hematin. Because hemozoin has an identical 
structure to synthetic -hematin, researchers concluded that hemozoin is the only 
detectable iron species within a trophozoite. These observations were further verified 
using microscopy, in which the distribution of iron within a trophozoite-infected RBC 
overlapped with hemozoin within the parasite and was devoid from the erythrocytic 
cytosol [32]. Another study used spinning disk confocal microscopy to acquire live 3D 
images of intraerythrocytic parasites. Using this technique researchers were able to 
measure the kinetics of hemozoin formation, observing the production of 1.5 fmols of 
hemozoin per parasite at the end its trophozoite stage [2]. 
Quantification of hemozoin from parasites in synchronized cultures shows low 
levels of production at early ring stages within the host RBC. Hemozoin noticeably 
appears at 15-19 hours post synchronization to rings. Production rapidly increases 
between 25-30 hours post synchronization, aligning with the time of trophozoite 
development and increased hemoglobin metabolism. Post hour 30, hemozoin levels 
plateau off [2]. After RBC lysis, hemozoin is released into circulation and can be picked 
up by phagocytes. Hemozoin crystals picked up by macrophages are toxic to these cells 
and can permanently damage and deplete their functionality. Other immunomodulatory 
effects of hemozoin have also been explored, such as the production of inflammatory 
cytokines and the inhibition of erythropoiesis leading to anemia and other malaria 
pathology [12]. 
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1.7 Blood stage antimalarials 
The use of antimalarials dates back to the 1600s with the discovery of a Cinchona 
bark extract known as quinine. It was from this natural remedy that future antimalarial 
drugs such as the widely used chloroquine were derived [33]. Chloroquine belongs to a 
larger class of antimalarials known as 4-aminoquinolines. This class includes other potent 
antimalarials such as piperaquine, amodiaquine, and pyronaridine [34]. Chloroquine is a 
weak base allowing it to easily permeate membranes, making its way into the acidic 
environment of the parasite digestive vacuole. Once protonated in the acidic digestive 
vacuole, chloroquine is unable to diffuse back out and therefore accumulates to lethal 
levels within the parasite [17]. It has been shown that chloroquine interaction with 
hematin inhibits crystal growth [35]. Because the conversion of toxic free heme to 
hemozoin is essential for parasite survival, disrupting this process with chloroquine is 
lethal to the parasite. This mechanism of action also applies to other potent 4-
aminoquinolines. It is therefore understandable that 4-aminoquinolines are most potent 
against the erythrocytic stages of the parasite life cycle.  
Chloroquine was deployed to treat malaria worldwide in the 1900s and was 
largely successful until resistance against the drug emerged in the 1960s. Chloroquine 
resistance was attributed to a single point mutation in the PfCRT gene coding for the 
chloroquine resistant transporter protein responsible for exporting protonated chloroquine 
from the digestive vacuole, preventing it from accumulating to high enough 
concentrations to be effective against the parasite [33]. Resistance to the most widely 
used antimalarial was devastating to the fight against malaria and therefore pushed 
researchers to seek alternative treatments. This eventually led to the discovery of 
 13 
artemisinin, derived a Chinese medicinal drug known as qinghao [33]. Artemisinin and 
other artemisinin derivatives such as artemether, artesunate, and dihydroartemisinin, are 
endoperoxides [34]. This class of drugs is activated by free heme which cleaves the 
endoperoxide bridge to form free radicals within the parasite to rapidly damage bystander 
proteins [33]. Similar to chloroquine, artemisinins are most effective against blood stage 
malaria. Because artemisinins must be activated by free heme, they are particularly potent 
during trophozoite stage where most hemoglobin degradation is occurring and large 
amounts of free heme are available. Unlike chloroquine, however, artemisinins do not 
directly bind hemozoin to inhibit its formation. Artemisinins are fast acting drugs with 
short half-lives and are therefore often paired with longer lasting drugs to create 
artemisinin combination therapies (ACTs) to ensure full parasite clearance.  
More recently, resistance to artemisinin treatment has emerged in Southeast Asia. 
This is was observed as significantly delayed parasite clearance in patients treated with 
artesunate in Western Cambodia as compared to patients who received the same 
treatment across the border in Thailand [36]. Upon genomic analysis of parasite strains 
isolated from resistant patients, a single point mutation in the Kelch 13 propeller region 
showed to confer resistance, the most commonly occurring SNP being a cysteine to 
tyrosine polymorphism at position 580 (C580Y) [37]. Because artemisinins are fast 
acting drugs, ring-stage assays were developed to measure drug inhibition immediately 
post invasion as opposed to the traditional IC50 which exposes higher concentration of 
drug for a longer period of time. Ring stage assays of strains with K13 mutations inserted 
into a wild type Cambodian background demonstrated longer survival of ring stage 
parasites after exposure to dihydroartemisinin (DHA) [38]. Therefore, the K13 mutation 
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conferred ring-stage resistance to artemisinin. Further studies showed altered parasite 
development in mutant strains. Resistant strains exhibited a prolonged ring stage and 
subsequently shorter trophozoite stage [39]. One hypothesis behind this mechanism could 
be that the parasites have adapted to reduce the amount of free heme exposed to 
artemisinin during hemoglobin degradation by reducing the amount of time spent in the 
trophozoite stage. 
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Artemisinin (ART) derivatives are fast-killing antimalarials that are currently the 
gold standard treatment against malaria. Therefore, development of ART resistance is of 
great concern, especially due to emerging evidence of this occurrence in Southeast Asia 
over the last several years. Artemisinins, as with other common classes of antimalarials, 
target the erythrocytic stages of the Plasmodium life cycle. As the parasite digests host 
red blood cell (RBC) hemoglobin within the acidic environment of its digestive vacuole, 
it releases toxic heme in the form of reduced iron (Fe
2+
). Heme activates ART by 
cleaving its endoperoxide bridge. ART radicals, derived from activation, damage 
surrounding proteins and effectively kill the parasite [1,2]. Because hemoglobin 
metabolism begins in the ring stage and largely occurs during the trophozoite stage, 
ARTs are effective in rapidly killing blood stage parasites: they can reduce parasite 
burden by 10,000-fold every 48 hours [3]. However, stage and time-dependence of ART 
killing is an important factor to consider when administering ART based treatment. 
Because ART has a short half-life (~1 hour in humans) and ring-stage parasites are less 
susceptible to ART killing, combination therapies are required to ensure true clearance of 
parasites. Therefore, ART-based combination therapies (ACTs) employ a partner drug 
[ex. mefloquine, piperaquine, lumefantrine] with a longer half-life that can eliminate 
residual parasites and prevent recrudescence [1,4]. 
In 2009, Dondorp et al. reported prolonged parasite clearance in patients treated 
with artesunate in Western Cambodia [4]. Specifically in the Pailin region of Western 
Cambodia, median parasite clearance was reported to be 84 hours as compared to 48 
hours in the Wang-Pha region of nearby Thailand, depicted in Fig. 2.1 [4].  
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Fig. 2.1 Parasite clearance curves.  
Taken from Dondorp et al. [4] 
 
To further explore this reduced susceptibility to ARTs, Witkowski et al. 
developed a novel “ring-stage assay” (RSA) to measure drug susceptibility 0-3 hours 
post-invasion as opposed to a traditional IC50 assay in which parasites are exposed to 
high concentrations of drug for 48-72 hours Using the RSA0-3h, they were able to 
successfully identify slow-clearing infections in Pursat, Cambodia. Rings cultured from 
these infections showed higher survival rates and therefore reduced susceptibility to a 6 
hour exposure to 700 nM dihydroartemisinin [5]. Genome wide- association studies were 
performed to identify the genetic drivers for ring stage resistance to ARTs. Ariey et al. 
observed four SNPs within a Kelch repeat of the K13 propeller domain: Y493H, R539T, 
I543T, and C580Y,  which associate with higher RSA0-3h survival rates [6]. 
Additionally, K-13 mutants clustered within areas of Cambodia in which delayed 
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clearance to ARTs was clinically observed [6]. These studies established specific K13 
polymorphisms as genetic markers of decreased ART susceptibility in western 
Cambodia. 
 Further studies involving genetic manipulation of culture-adapted Cambodian 
isolates revealed lower ring-stage survival after exposure to DHA upon removal of K13 
SNPs I543T and C580Y. The mutations were also introduced into fast-clearing wild type 
isolates and an increase in RSA0-3h survival was subsequently observed [7]. These 
studies further verified the causal role of K13 SNPs in conferring ring-stage artemisinin 
resistance. However, the molecular mechanisms of this phenomenon have not been 
completely elucidated. Transcriptomic studies by Mok et al. revealed decelerated 
development of resistant parasites and upregulation within a protein pathway involving 
Plasmodium reactive oxidative stress complex (PROSC) and TCP-1 ring complex (TRiC) 
[8]. Altered intraerythrocytic development in resistant parasites from Cambodian clinical 
isolates was also observed by Hott et al [9]. Morphological observations revealed a 
prolonged ring stage and compressed trophozoite stage as schizogony was completed 
simultaneously to an artemisinin susceptible strain. The ring-stage in resistant parasites 
lasted up to 14 hours longer (30 hours total) than the control [9]. Because the parasite life 
cycles were synchronized and schizogony occurred simultaneously, time for trophozoite 
development in resistant parasites was shortened. Hott et al. hypothesize that perhaps 
parasites have evolved to reduce ART exposure to the trophozoite stage. After all, 
increased metabolism during trophozoite stages releases the free heme needed to activate 
ART drugs. Therefore, by reducing heme exposure to ART, the parasite is potentially 
able to avoid damage caused by activated ART.  
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Antimalarials such as the 4-aminoquinolines target hemozoin production by 
inhibiting crystal growth allowing for the accumulation of toxic free heme within the 
parasite digestive vacuole [10]. As previously discussed, artemisinins are activated by 
free heme to form damaging radicals. Therefore, the hemoglobin digestion and hemozoin 
formation pathway are prime targets for antimalarials. If the parasite alters this process, it 
could potentially attenuate the efficacy of antimalarials. Plasmodium has evolved to 
confer resistance to previous and current antimalarials by developing ways to avoid or 
overcome drug pressure. These parasite stress responses remain to be elucidated. In this 
project, we aim to consider altered hemozoin production as a possible stress response to 
confer resistance. We asked whether drug resistant Plasmodium falciparum strains with 
compressed trophozoite stages produce hemozoin with altered morphology. We 
hypothesized that altered development of parasites due to drug resistance would effect 
hemozoin production and therefore produce crystals of altered shape or size as compared 




Sources of hemozoin 
P. falciparum strains CamWT and C580Y were maintained in culture at 2% 
hematocrit in RPMI 1640 media supplemented with L-glutamine, 25mM HEPES, 0.25% 
NaHCO3, 0.37 mM hypoxanthine, 50 ul of 50 mg/ml gentamycin, and 10% human 
serum. Cultures were incubated at 37°C in 5% CO2/5% O2/Balanced N2. P. falciparum 
cultures were synchronized to ring stage by incubation in 5% sorbitol. Parasitemia was 
assessed by light microscopy of a Giemsa-stained blood film. Trophozoites were isolated 
by saponin lysis and pelleted to be stored at -80°C until processed for purifying 
hemozoin. Purified hemozoin for FCR3 and ITG were provided by Dr. David Sullivan 
for FEISEM images. FEISEM images of previously imaged strains 3BD, 3D7, D10, 
FCB, 106/1, and P. berghei NYU-2 were provided by Dr. David Sullivan for analysis. 
Hemozoin purification 
Pellets from saponin lysed cultures were thawed at room temperature before 
processing. Each pellet was washed by adding 1 ml 2% sodium dodecyl sulfate (SDS), 
then briefly sonicated, followed by centrifugation at 13000 rpm for 5 mins. The 
supernatant was removed and discarded and the SDS wash was repeated. After 2x SDS 
washes, 1 ml of proteinase K (Invitrogen cat no. 25530-031, 1 mg/ml in proteinase K 
buffer solution of 10 mM TrisHCl, 0.5% SDS, and 1 mM CaCl2) was added to each 
sample, vortexed, and then incubated in a 56°C water bath overnight. The following day, 
the samples were removed from the water bath and centrifuged at 13000 rpm for 5 mins. 
Once the supernatant was removed, 2x more SDS washes were performed using the same 
method as mentioned. Following the SDS washes, a water wash was performed by 
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adding 1 ml water to each pellet, sonicating, centrifuging at 13000 rpm for 7 mins, and 
discarding the supernatant very carefully. Water washes were performed until the 
supernatant looked clear with a visible pellet remaining. A maximum of 6x water washes 
were performed. After the final wash, the purified hemozoin pellet was resuspended by 
sonication in 1ml water.     
Hemozoin quantification 
The purified hemozoin samples were briefly sonicated before quantification. Each 
sample was plated at 10 ul, 20 ul, and 30 ul in a clear, flat-bottom 96-well plate. The 
samples were de-crystallized in the 96-well plate by adding 2% SDS/50mM NaOH (pH 
9.0) to each well, with a total volume of 200 ul per well. A standard curve was developed 
by creating a serial dilution of hemin in 2% SDS at concentrations ranging from 10 nmols 
to 0.1 nmols hemin per well. 100 ul 2% SDS was plated as a negative control. 
2%SDS/50mM NaOH was also added to the hemin standard curve and negative control 
to total 200 ul per well. All samples, as well as the standard curve and negative control 
were analyzed in duplicate wells. The plate was incubated at room temperature for 30 
mins. Successful de-crystallization had occurred if the samples were visibly green in 
color after incubation. After incubation, the plate was read on the SpectraMax M2 plate 
reader to measure absorbance at 405 nm. The lower limit of detection was determined to 
be at an optical density (OD) of 0.2 and saturation occurred at an OD of 2.5. Hemozoin 
samples were quantified by using a linear regression equation of the hemin standard 
curve at concentrations between 10 nmol to 1 nmol per well to calculate the concentration 
of hemozoin per well. 
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Field Emission In-lens Scanning Electron Microscope (FEISEM) imaging 
Hemozoin was coated on silica chips following a previously described protocol 
[11]. 7-8 nmols hemozoin were coated on each chip. Hemozoin coating was verified 
using microscopy. After critical point drying, the hemozoin containing chips were coated 
with gold and imaged on the FIESEM (Leo 1550). About 15 to 20 images were taken per 
sample.    
Hemozoin measurements 
The image analysis software ImageJ was used to measure hemozoin dimensions. 
Images were magnified so that roughly 20 pixels was equivalent to 100nm. The line-
drawing tool was used to measure the scale on each image to produce a pixel equivalent 
value. The line-drawing tool was then used to measure 3 lengths and 3 widths per crystal 
as depicted in Fig. 2.2. The software automatically converted the measurements to nm, 
which were then averaged to produce one measurement of length and one measurement 
of width per crystal.  
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Fig. 2.2 FEISEM images of Pf hemozoin and ImageJ analysis. 
Representative images taken with FEISEM were analyzed by using ImageJ to draw lines 
along the lengths and widths of each crystal. Three measures were taken for each crystal 
length and width: two on each edge and one down the center. The three measures were 




Data was analyzed using GraphPad Prism (v6). Individual crystal measurements 
were plotted along with the mean ± SEM for each sample. Unpaired t-tests were 





Hemozoin in isogenic drug resistant Plasmodium is smaller in size 
The first two isogenic strains we compared were ring-stage artemisinin sensitive 
PfCamWT and ring-stage artemisinin resistant PfC580Y which differ by a single 
Kelch13 point mutation [6,7]. Upon measurement of the lengths and widths of the 
hemozoin crystals from each strain, C580Y hemozoin crystals were smaller than 
CamWT, with a statistically significant difference in width between the two strains. 
Individual and mean ± SEM lengths and widths of CamWT and C580Y hemozoin can be 
found in Fig. 2.3.  
 
Fig. 2.3 Comparison of hemozoin dimensions of P. falciparum strains CamWT and 
C580Y. 
Hemozoin crystal lengths and widths are presented in nm for the isogenic Pf strains: ring-
stage artemisinin sensitive Cambodian Wild Type (CamWT) and ring-stage artemisinin 
resistant C580Y.  Each point represents the measurement of an individual hemozoin 
crystal with mean ± SEM displayed. Statistical analysis was conducted using an unpaired 
t-test to compare length and width measures between strains. (A) Mean hemozoin length 
was 556.5nm ± 19.2nm for CamWT and 532.8nm ± 15.7nm for C580Y. Statistical 
analysis resulted in a p-value of 0.341 (ns). N=50 individual crystals were measured for 
each strain. (B) Mean hemozoin width was 131.7nm ± 4.3nm for CamWT and 113.1nm ± 
3.2nm for C580Y. Statistical analysis resulted in a p-value of 0.0008. N=54 individual 
crystals were measured for each strain.  
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Chloroquine sensitive (CQS) Pf106/1 was compared to chloroquine resistant 
(CQR) PfFCB. Resistance in PfFCB is conferred by a K76T point mutation in the Pfcrt 
gene, providing us with another comparison of hemozoin dimensions between isogenic Pf 
strains but with different drug susceptibilities [12]. In this case, FCB hemozoin was 
significantly smaller in both width and length as compared to 106/1 hemozoin as depicted 
in Fig. 2.4. 
 
Fig. 2.4 Comparison of hemozoin dimensions of P. falciparum strains 106/1 and 
FCB.  
Hemozoin crystal lengths and widths are presented in nm for the isogenic Pf strains: 
chloroquine sensitive 106/1 and chloroquine resistant FCB.  Each point represents the 
measurement of an individual hemozoin crystal with mean ± SEM displayed. Statistical 
analysis was conducted using an unpaired t-test to compare length and width measures 
between strains. (A) Mean hemozoin length was 476.1nm ± 15.2nm for 106/1 and 
412.6nm ± 14.0nm for FCB. Statistical analysis resulted in a p-value of 0.003. N=50 
individual crystals were measured for each strain. (B) Mean hemozoin width was 
112.7nm ± 2.9nm for 106/1 and 98.3nm ± 3.0nm for FCB. Statistical analysis resulted in 
a p-value of 0.0007. N=70 individual crystals were measured for each strain.  
 
A third comparison of hemozoin dimensions between isogenic strains was made 
with P. berghei. CQR P. berghei NYU-2 was developed by keeping the CQS parent 
strain under chloroquine pressure in a mouse model [13,14]. Chloroquine resistance is 
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reversible and postulated to be transcriptional rather than by SNP because the PbCRT 
gene is unaltered. Hemozoin crystals from the CQR PbNYU-2 strain were also observed 
to be smaller than the CQS strain, with statistically significant differences in both crystal 
length and width (Fig. 2.5). 
 
Fig. 2.5 Comparison of hemozoin dimensions of CQS and CQR P. berghei NYU-2 
strains. 
Hemozoin crystal lengths and widths are presented in nm for the isogenic Pb strains: 
CQS PbBYU-2 and CQR PbNYU-2.  Each point represents the measurement of an 
individual hemozoin crystal with mean ± SEM displayed. Statistical analysis was 
conducted using an unpaired t-test to compare length and width measures between 
strains. N=79 and n=83 individual crystals were measured for each strain respectively. 
(A) Mean hemozoin length was 295.8nm ± 7.5nm for CQS PbNYU-2 and 256.6nm ± 
6.9nm for CQR PbNYU-2. Statistical analysis resulted in a p-value of 0.0002. (B) Mean 
hemozoin width was 101.6nm ± 2.2nm for CQS PbBYU-2 and 72.6nm ± 1.7nm for CQR 
PbNYU-2. Statistical analysis resulted in a p-value of <0.0001. 
 
Hemozoin dimensions of non-isogenic P. falciparum strains 
Hemozoin dimensions of CQS Pf strains NF54, 3D7, and HB3 were compared to 
those of CQR Pf strains ITG, DD2, FCR3 (Fig. 2.6). The CQR strains were not isolated 
clones of the CQS strains being compared. No significant difference was observed 
between the lengths nor the widths of crystals in comparisons between each individual 
 33 
CQS strain to each CQR strain as well as a comparison between mean crystal size of all 
non-isogenic CQS to CQR strains. Analyzed images of the non-isogenic strains can be 
found in Fig. 2.7.  
 
Fig. 2.6 Comparison of hemozoin dimensions of non-isogenic P. falciparum strains. 
Hemozoin crystal lengths and widths are presented in nm for the non-isogenic 
chloroquine sensitive (CQS) Pf strains NF54, 3D7, HB3 and chloroquine resistant (CQR) 
Pf strains ITG, DD2, FCR3. Each point represents the measurement of an individual 
hemozoin crystal with mean ± SEM displayed. Statistical analysis was conducted using 
an unpaired t-test to compare length and width measures between sensitive and resistant 
strains. (A) Mean hemozoin length was 492.7nm ± 25.5nm for NF54, 470.1nm ± 29.7nm 
for 3D7, and 440.5nm ± 70.6nm for HB3. N=50, n=38, and n=5 individual crystals were 
measured for each respective CQS strain. Mean hemozoin length was 499.5nm ± 21.9nm 
for ITG, 461.6nm ± 16.7nm for DD2, and 464.2nm ± 22.6nm for FCR3. N=50, n=3, and 
n=5 individual crystals were measured for each respective CQR strain. No significant 
difference of crystal length was found between any CQS and CQR strains. (B) Mean 
hemozoin width was 114.1nm ± 4.9nm for NF54, 117.0nm ± 6.0nm for 3D7, and 
122.9nm ± 13.3nm for HB3. N=25, n=45, and n=5 individual crystals were measured for 
each respective CQS strain. Mean hemozoin length was 115.2nm ± 5.8nm for ITG, 
100.8nm ± 9.7nm for DD2, and 105.8nm ± 4.6nm for FCR3. N=25, n=5, and n=30 
individual crystals were measured for each respective CQR strain. No significant 




Fig. 2.7 Analyzed FEISEM images of non-isogenic Pf hemozoin. 
Representative images of non-isogenic CQS and CQR Pf strains taken with FEISEM and 
analyzed using ImageJ. Markings used to measure crystal lengths and widths are visible 





In this study we explored altered hemozoin production as a parasite stress 
response. This stems from the hypothesis that ring-stage artemisinin resistant parasites 
with shortened trophozoite stages exhibit altered hemozoin production. Because most 
hemozoin production occurs during the trophozoite stage, we predict that lesser time 
spent as a trophozoite would yield lesser amounts of hemozoin. However, it has been 
reported that ring-stage artemisinin resistant parasites with altered development produce 
the same amount of hemozoin as susceptible parasites with normal development [15]. 
Therefore, we explored the morphology of the hemozoin crystals being produced in order 
to learn more about the nucleation process of resistant parasites.  
  We began by measuring hemozoin dimensions from C580Y, a ring-stage 
artemisinin resistant strain, and found that hemozoin crystals were significantly smaller 
than the artemisinin susceptible CamWT. Additionally, we measured crystals from 106/1 
and FCB, isogenic strains where a single point mutation K76T confers chloroquine 
resistance in FCB. In these isogenic strains we saw similar results in that the chloroquine 
resistant strain FCB produced smaller sized hemozoin crystals than 106/1. Therefore, we 
observed that a single point mutation which confers resistance may be sufficient to 
produce smaller sized hemozoin crystals as was seen in both C580Y and FCB as 
compared to their respective susceptible strains. Smaller sized hemozoin crystals were 
also observed in isogenic P. berghei resistant strains. However, hemozoin sizes were not 
significantly different when comparing non-isogenic chloroquine sensitive and resistant 
P. falciparum strains. Therefore, it may be that a single point mutation which confers 
resistance is necessary to produce smaller sized crystals. However, this needs to be 
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further explored in more drug susceptible and resistant isogenic strains to confirm that 
this is the case.  
The implications of this research concern the mechanisms by which hemozoin is 
produced and how this is altered under drug pressure to confer resistance. The details 
underlying the process of hemozoin production remain to be clarified, however, there is 
increasing evidence of neutral lipid bodies in the digestive vacuole which promote 
hemozoin formation [16]. We hypothesize that hemozoin nucleation sites are producing 
smaller sized crystals as a result of a single point mutation which confers drug resistance. 
It has been reported that in C580Y, the same total amount of hemozoin is produced as 
CamWT [15]. In order to produce the same amount of total hemozoin while producing 
smaller sized crystals, we hypothesize an increase in the number of hemozoin nucleation 
sites within the digestive vacuole to compensate for hemozoin production during a 
shortened trophozoite stage. By increasing the number of hemozoin nucleation sites, 
parasites can potentially overcome pressure under drugs targeting hemoglobin 
degradation and hemozoin production by increasing their ability to continue these 
essential processes.  
To further verify whether smaller sized hemozoin crystals are truly a product of 
single nucleotide polymorphisms in drug resistant parasites, we would like to measure 
hemozoin crystals of more drug susceptible and resistant isogenic P. falciparum strains. 
We would also like to confirm the total amounts of hemozoin being made by parasites 
with altered development. Finally, we would like to see whether drug pressure on 
susceptible strains alters hemozoin production. We attempted to do this by adding 1uM 
drug (chloroquine, artesunate, pyronaridine) to C580Y cultures for a 4 hour drug pulse at 
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trophozoites. However, we believe this dose may be too strong to potentially observe 
changes in hemozoin production. Applying drug at lower concentrations and during early 
ring into trophozoite stages may allow us to collect a measurable amount of hemozoin for 
morphology analysis. We predict that with constant drug pressure on sensitive strains, the 
parasites may develop the ability to produce smaller sized crystals. Measuring the total 
amount of hemozoin production along with the sizes of the crystals produced will provide 
further insight into how hemozoin is produced and how this process is altered as a 
parasite becomes drug resistant.       
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QUANTIFYING THE COMPARTMENTAL KINETICS OF HEMOZOIN 
DURING CLEARANCE OF INFECTION  
 42 
INTRODUCTION 
To improve on current diagnostics, hemozoin is a potential biomarker for malaria 
infections. However, the most popular methods of hemozoin detection have their limits if 
they were to be used as diagnostics. Where mass spectrometry and powerful microscopy 
are efficient ways of detecting hemozoin, they are not feasible to conduct in the field as 
malaria diagnostics. Exploiting the magneto-optical properties of hemozoin as a 
molecular biomarker is currently being explored [1]. To further establish hemozoin as a 
molecular biomarker of malaria, it is important to understand its kinetics during infection. 
Historically, autopsies of malaria patients have shown darkly pigmented organs such as 
the brain, liver, and spleen [2]. In blood, hemozoin can be ingested by monocytes and 
macrophages as these immune cells are phagocytosing infected and lysed RBCs. In 
tissue, resident macrophages may also be picking up hemozoin resulting in sequestered 
pigment within the organs[3]. It is hypothesized that hemozoin can have 
immunomodulatory effects on macrophages by suppressing their activity. Therefore, 
studying the kinetics of hemozoin in blood and tissue during infection can have important 
implications on further understanding the immune responses to Plasmodium infection.  
Several studies have looked into hemozoin levels in blood and tissue of mouse 
models to quantify hemozoin during the course of an infection. One study used a 
fluorometric assay converting hemozoin to protoporphryn IX to measure its fluorescence 
[4]. In this study, mice were infected with two rodent malaria strains: P. berghei NK65 
and P. berghei ANKA. They collected whole blood, livers, and spleens at different time 
points in the PbNK65 infected mice. These mice were followed out until day 18 post 
infection. The PbANKA model was used to look at hemozoin in cerebral malaria. This 
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study showed that over the course of 18 days, hemozoin concentration in the livers and 
spleens of infected mice increased exponentially, and that this correlated with the 
duration of infection [4]. It seemed that hemozoin accumulated more rapidly in the 
spleen, but greater overall accumulation occurred in the liver at day 18. 
Another study looked at long term levels of hemozoin in the livers and spleens of 
mice infected with P. yoelii and P. chabaudi after infection had cleared [5]. In P. yoelii 
infected mice there was no change in liver concentration of hemozoin, however there was 
a 5-fold increase in spleen concentration at day 270 post parasite clearance. In the P. 
chabaudi infected mice, there was a 70% decrease in liver concentration and a 3-fold 
increase in spleen concentration at day 270 as well. A decrease in liver concentration and 
increase in spleen concentration suggests that hemozoin may translocate from the liver to 
the spleen. This study also showed that hemozoin can persist in the tissues up to 9 months 
after clearance of infection [5]. Another study of the long term kinetics of hemozoin 
presented similar findings in that hemozoin levels decreased in the liver and increased in 
the spleen but was present up to 196 days after chloroquine treatment [6].  
The transport of hemozoin from the liver to the spleen during clearance of 
infection presumably occurs via the blood. Hemozoin in whole blood can be quantified 
by spectrophotometry. However, in one of the studies quantifying hemozoin in blood, no 
hemozoin was quantified in up to 320ul of plasma [7]. It is possible that hemozoin may 
exist in plasma as residual parasite proteins and hemozoin are left in a once-infected RBC 
after rupture. Therefore, spectrophotometry may not have been a sensitive enough 
method to quantify hemozoin in plasma. In exploring more sensitive assays to quantify 
hemozoin, luminescence based assays seem promising. Luminol is a substance that can 
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react with heme iron and exhibit chemiluminescence under the appropriate conditions. 
Interestingly, luminol is commonly used by forensic scientists to detect trace amounts of 
blood. The reaction between luminol and heme iron can be exploited to create a more 
sensitive quantitative assay for hemozoin. Deroost et al. were able to show that a heme-
enhanced luminescence based system could quantify hematin down to concentrations of 
100 nM as compared to 1 uM concentrations quantified using absorbance [8].  
The goal of this project was to use the heme-enhanced luminescence based system 
to develop a sensitive assay for hemozoin quantification in human and mouse whole 
blood fractions. By developing a more sensitive quantitative assay, we aim to compare 
hemozoin concentrations between the RBC and plasma fractions of whole blood. We 
hypothesize that during initial clearance of infection, hemozoin will be more concentrated 
in the RBC fraction. However, after clearance through the spleen, residual hemozoin may 
be present in the plasma. This project will allow for us to better understand the 
compartmental kinetics of hemozoin during clearance of infection, with larger 
implications of understanding the general kinetics of hemozoin to develop diagnostics 





 De-identified human patient whole blood samples were collected under the 
approved Johns Hopkins School of Public Health IRB protocol #9164. Animal 
experiments were performed under the approved protocol MO16H91. 
Patient blood collection 
Plasmodium infected human patient whole blood samples were collected from the 
Johns Hopkins Hospital Microbiology Lab and de-identified. 50 ul whole blood was 
aliquoted and the rest of the sample was centrifuged at 7600 rpm for 4.5 mins to separate 
into RBC and plasma fractions. The RBC fraction was washed with PBS a total of 4 
times. All samples were stored in -80°C until processing.  
Although the patient samples were de-identified, information such as Plasmodium 
species of infection, date and time of blood draw, treatment, days post treatment, and 
parasitemia were included upon collection. 
Mouse tissue and blood collection 
Mice treated with a curative dose of pyronaridine were sacrificed at 0, 1, 2, 4, 7, 
10, 13, 25, 86, and 100 days post treatment to harvest their livers, spleens, and whole 
blood for hemozoin quantification. Tissue masses were recorded upon harvest. 100ul 
whole blood was aliquoted for hemozoin purification and the rest was fractionated into 
RBC and plasma aliquots as previously described. In contrast to the human samples, the 
RBC fraction was not washed with PBS to preserve any white blood cells (WBCs). All 
samples were stored at -80°C until processing. 
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A total of 127 mice were used for this study. The mice were classified into 
different groups based on initial parasitemia and development of infection. Single peak 
parasitemia occurred in mice that were treated when a single curative dose of 
pyronaridine was given at peak parasitemia. Double peak parasitemia occurred in mice 
that were drug treated at the first peak of parasitemia, followed by a decline in parasite 
burden, after which infection recurred to a second peak at which time they were treated 
with a curative dose of pyronaridine. A summary of the mouse harvests can be found in 
Table 3.1. 
Table 3.1 Mouse experiment summary. 
The number of processed samples for liver, spleen, whole blood, RBC, and plasma per 
day post treatment in P. berghei infected white mice are presented. 
 
Hemozoin purification 
All samples were thawed and processed to purify and quantify hemozoin. The 
protocol with which hemozoin was purified from blood and tissue was adapted from 
Pisciotta et al. [7] Mouse livers and spleens were homogenized in 5 ml and 1 ml of water 
respectively using pulse sonication (Branson Sonifier 250). They were then centrifuged at 
13000 rpm for 10 mins after which the supernatant was discarded. 1 ml 2%SDS/100mM 
sodium bicarbonate (pH 9.2) was added to each sample and sonicated. Samples were 
centrifuged at 13000 rpm for 5 mins. The supernatant was discarded along with any 
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solubilized free heme within it. 1 ml proteinase K dissolved in protease K buffer (10 mM 
Tris pH 8, 0.5% SDS, 1 mM CaCl2) at 1 mg/ml was added to each sample and sonicated. 
The samples were left to incubate in a 60°C water bath overnight. After incubation, 
samples were centrifuged at 13000 rpm for 5 mins and the supernatant was discarded. 
Another 1ml of 2%SDS/100mM sodium bicarbonate was added to each sample and 
sonicated. After centrifugation the supernatant was removed. At least two more wash 
steps were performed with 1ml 2% SDS until the supernatant was clear after 
centrifugation. After the final wash, purified hemozoin from livers and spleens were 
resuspended in 1 ml and 500 ul of 2% SDS respectively and sonicated. 
All whole blood, red blood cell (RBC), and plasma samples were purified using a 
similar but modified version of the previously described protocol. The samples were 
lysed with water by bringing each sample up to 1 ml. An additional 10 ul of 10% SDS 
was added to each mouse sample. Samples were vortexed and centrifuged at 13000 rpm 
for 5mins and the supernatant was discarded. 2x 2%SDS/100mM sodium bicarbonate 
washes and 2x 2% SDS washes were performed as previously described. After the final 
wash, samples were resuspended in 250ul 2%SDS/50mM NaOH and vortexed. With each 
processing batch of whole blood, RBC, and plasma samples, at least two positive and two 
negative controls were processed as well. For the whole blood negative controls, 200ul of 
uninfected human RBCs at 50% hematocrit in PBS was processed. For the RBC negative 
controls, 100 ul of uninfected human packed RBCs was processed. For the plasma 
controls, 100 ul of uninfected human serum was processed. Positive controls were created 
by adding 10 nmol of -hematin to each negative control condition.  
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Hemozoin quantification using absorbance 
Highly concentrated samples with a visible black hemozoin pellet after 
purification were quantified using visible spectrophotometry at 405nm. 10-50 ul of each 
sample were plated in duplicate in a 96-well clear flat-bottom plate. Each well was 
brought up to a volume of 200 ul with 2%SDS/50 mM NaOH to de-crystallize the 
hemozoin. A hemin standard curve was developed and plated in duplicate within a 
concentration range of 0.8 – 10 nmol/well. 100 ul of 2% SDS was also plated in duplicate 
to measure background noise. Both the hemin standards and 2% SDS wells were also 
brought up to 200 ul in 2%SDS/50 mM NaOH. The plate was left to incubate at room 
temperature for 30 mins before being read on the SpectraMax M2 plate reader. Hemozoin 
concentration of samples with an optical density within the limits of quantification was 
determined by developing a linear regression of the hemin standard curve. The linear 
regression equation was used to calculate the hemozoin concentration of each well from 
the mean optical density of each pair of duplicate wells. Samples which were too highly 
saturated were diluted down to the quantifiable range of measuring hemozoin with 
absorbance.   
Hemozoin quantification using luminescence  
Samples in which there was no visible hemozoin were quantified with a luminol 
assay we optimized from [8]. After having been already de-crystallized in 2%SDS/50 
mM NaOH, a maximum of 200 ul of each sample was plated in a 96-well black flat-
bottom plate. A hemin standard curve was also developed for this assay and was plated in 
duplicate at ranges from 0.8-10 pmol/well. Additionally, 100 ul 2% SDS was plated in 
duplicate to measure background noise. Wells containing the hemin standard curve and 
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2% SDS were brought up to 200 ul in 2%SDS/ 50 mM NaOH. 75 ul of luminol at 
100ug/ml in luminol reagent (4 volumes of 100 mM NaOH, 2% SDS, 3 mM EDTA to 1 
volume of 1M Na2CO3) was added to each well [8]. Immediately before reading the plate, 
25 ul of 7% H2O2 (diluted from a 31% stock in the same 4:1 luminol reagent) was added 
to each well. Peroxide is catalyzed into oxygen by Fe
3+
, which reacts with the luminol to 
produce luminescence. We captured the luminescence emitted from each well with a 1s 
exposure on the IVIS Spectrum imager. The software program Living Image was used to 
quantify luminescence in photons/sec for each well. Similar to the absorbance assay, we 
used a linear regression equation from the hemin standard curve to quantify the amount 
of hemozoin in each well from which we were able to determine the hemozoin 
concentration of the original sample. 
Data analysis 
Samples were quantified against a hemin standard curve developed for each 
appropriate assay. For all blood samples processed, average background luminescence 
from the negative controls processed with that batch of samples was subtracted from 
individual luminescence of each infected sample before calculating hemozoin 




Luminol assay is a more sensitive method of hemozoin quantification than 
absorbance. 
 
Fig. 3.1 Hemin standard curves. 
Standard curves were developed with hemin for hemozoin quantification assays. (A) 
Hemin standard curve for quantification using absorbance. Mean OD values for 10 
biological replicates were plotted with error bars depicting SEM. R
2
 for this linear 
regression model (solid line) was 0.97. Average LOD for replicate runs was 0.052 
(dashed line). (B) Hemin standard curve for quantification using luminescence. Mean 
luminescence in photons/sec for 11 biological replicates were plotted with error bars 
depicting SEM. R
2
 for this linear regression model (solid line) was 0.80. Average LOD 
for replicate runs was 8.250e7 (dashed line). (C) Hemin standard curve on luminol assay 
is representative to luminescence from -hematin at equivalent concentrations. (D) Time 
course of hemin luminescence. 1 sec. exposure with 1 sec. delay of hemin was analyzed 
over the course of 5 mins. 
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Two methods of hemozoin quantification were utilized for this project. First, 
hemozoin was quantified by measuring its optical density after de-crystallization. A 
standard curve for this assay was developed using hemin. Background from 100 ul 2% 
SDS was measured in duplicate on each plate and averaged over 10 plates to get an 
optical density of 0.046. The LOD of each plate was determined by adding three standard 
deviations to the mean background value resulting in a mean LOD of 0.052, as depicted 
as the dashed line in Fig. 3.1A. By plating a range of hemin concentrations, the lower 
limit of quantification was determined to be 600 pmol hemin in 200 ul per well with an 
OD of around 0.2. Any samples with an OD of under 0.2 were considered to be too low 
in concentration to be quantifiable by absorbance. Saturation occurred at an OD of 2.5, 
therefore samples with an OD above this value were diluted down to be re-quantified. A 
hemin standard curve with concentrations ranging from 2 nmol to 10 nmol on each plate 
analysis was used to create a linear regression model with which unknown samples could 
be quantified.  
A similar method was used to develop a hemin standard curve for the luminol 
assay. The lower limit of quantification by luminol was determined to be at a hemin 
concentration of 400 fmol in 200 ul per well with a luminescence of around 2.25e8 
photons/sec. Saturation in the luminol assay occurred at around 4e9 photons/sec. The 
mean limit of detection over 11 replicates of standard curves was 8.250e7 as depicted 
with the dashed line in Fig. 3.1B. By developing this standard curve we were able to 
establish that the luminol assay is a one thousand-fold more sensitive method of 
quantification of heme with an LOQ of 400 fmol as compared to absorbance which has 
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an LOQ of 600 pmol. This one thousand-fold increase in sensitivity allowed us to 
quantify heme samples that were too low to have a detectable optical density. 
Luminescence of hemin was compared to that of -hematin to ensure the hemin 
standard curve would accurately represent hemozoin concentrations. Known equivalent 
amounts of hemin and -hematin were analyzed on the luminol assay. As shown in Fig. 
3.1C, luminescence values for both hemin and -hematin overlap nicely at equivalent 
concentrations within quantifiable range. 
A time course was performed with a 1 second exposure and 1 minute delay over 5 
minutes with a range of hemin concentrations. As presented in Fig. 3.1D, luminescence 
peaks at the first exposure and then gradually declines.  
Hemozoin is transported from the liver to spleen via whole blood during clearance 
of infection.
 
Fig. 3.2 Total hemozoin content in mouse livers and spleen. 
(A) Mean values of total hemozoin (in pmol) purified from tissue is plotted per day post 
pyronaridine treatment. Error bars indicate SEM. (B) Mean values of tissue weights taken 
at time of harvest is plotted with error bars indicating SEM. N of samples at each day can 
be found in Table 3.2.  
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Hemozoin was isolated from livers and spleens of mice after 0, 1, 2, 4, 7, 10, 13, 
25, 86, and 100 days post treatment with a curative dose of pyronaridine. Hemozoin 
isolated from livers and spleens was quantified using absorbance. Figure 3.2A presents 
total hemozoin content isolated from the full livers and spleens. The weight of each 
individual organ was recorded at the time of harvest (Fig 3.2B). Livers weighed between 
800 mg – 1g during the first two weeks post treatment after which the sizes grew smaller. 
Spleens weighed around 600 mg during the first 4 days post treatment with the exception 
of day 2 spleens which were similar in weight to the livers at day 2. After day 4, spleen 
weight declined as well.  There appears to be more total hemozoin in the liver up to day 
10 post treatment after which the total amount of hemozoin is the same in the liver and 
the spleen.  
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Fig. 3.3 Hemozoin concentration in mouse livers, spleens, and whole blood. 
(A) Isolated hemozoin from mouse livers and spleens was quantified using absorbance. 
Mean values of pmol hemozoin per mg tissue processed from individual mice are plotted 
for each day post treatment. Error bars represent SEM. (B) Isolated hemozoin from 100 
ul whole blood (WB) was quantified using luminescence. Mean values of pmol hemozoin 
per ul WB processed are plotted for each day post treatment. Error bars represent SEM.  
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Table 3.2 Mean ± SEM hemozoin concentration in liver, spleen and WB. 
Liver and spleen samples were quantified using absorbance and are presented in pmol 
hemozoin per mg tissue processed. WB samples were quantified using luminescence and 
are presented as pmol hemozoin per ul WB processed. 
 
 
Fig. 3.3A presents the hemozoin concentration normalized to tissue weight. There 
is a significantly larger amount of hemozoin concentrated in the liver during the first four 
days of clearance post treatment. After day 7, hemozoin concentrations in the spleen 
increase to larger amounts than the liver. Concentrations in the liver peak at day 10 and 
then decline. An additional peak in both liver and spleen concentrations is observed at 
day 86, followed by a decline to day 100.  
Hemozoin from 100ul whole blood was also isolated for each mouse. Fig. 3.3B 
presents quantification of hemozoin by luminescence from these samples by plotting the 
mean values from individual mice over the course of clearance. Hemozoin levels were 
extremely high on day 0 relative to the rest of the days. Hemozoin concentration in whole 
blood rapidly declines on day 1 and continues to do so until day 4. This is followed by an 
increase and subsequent peak in hemozoin concentration between days 4 and 10 after 
which hemozoin levels decline again and remain constant out through day 100. 
Hemozoin concentrations presented in Fig. 3.3B were calculated after subtracting out 
background luminescence. The number of samples which remained positive above the 
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background threshold and the mean hemozoin concentrations of these samples can be 
found in Table 3.2.  
 
Fig. 3.4 Single and double peak parasitemia in P. berghei infected mice. 
Mice were classified into two groups of parasitemia. Parasitemia was determined by 
luciferase and is presented in parasites/ul of blood. Baseline detection of the luciferase 
assay is plotted as the dashed line (---) at 1000 parasites/ul. This figure presents 5 
representative mice from each group. The red arrow indicates when pyronaridine was 
given. (A) Single peak mice received pyronaridine at peak parasitemia after which 
parasite concentration decreased (B) Double peak mice received pyronaridine at the 
second peak of parasitemia after recurrence of infection. 
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Fig. 3.5 Parasitemia of individual mice compared to hemozoin concentration in 
liver, spleen, and whole blood. 
Parasite burden for each mouse was calculated by determining the area under the 
parasitemia curve before pyronaridine treatment. AUC was converted to parasites/ml of 
blood. Parasitemia in mice was determined using a luciferase assay. (A) Parasite burden 
of all individual mice is plotted against matched liver concentrations. (B) Parasite burden 
of all individual mice is plotted against matched spleen concentrations. (C) Parasite 
burden of all individual mice is plotted against matched WB concentrations. 
 
We wanted to determine whether total parasite burden correlated with the amount 
of hemozoin present in mouse tissue and whole blood. Mice were classified into single 
and double peak parasitemias of which the area under the curve (AUC) was calculated in 
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parasites/ul. Single peak mice received pyronaridine at peak parasitemia after which 
parasite concentration decreased (Fig. 3.4A). The average area under the curve for all 
single peak mice was roughly 2 million parasites/ul. Single peak mice were harvested at 
days 0, 25, and 100 post drug treatment. Double peak mice received pyronaridine at the 
second peak of parasitemia after recurrence of infection (Fig. 3.4B). The average area 
under the curve for all double peak mice was roughly 9 million parasites/ul. Double peak 
mice were harvested at days 0, 1, 2, 4, 7, 10, 13, and 86 post drug treatment. Naturally, 
single peak mice had an overall lower parasite burden than double peak mice due to 
recurrence of infection in the double peak mice. There is no general trend between 
parasite burden and hemozoin concentration in the livers, spleens, and whole blood (Fig 
3.5). This relationship was also analyzed by each day and no significant trend was found. 
High hemozoin concentration in whole blood may be attributed to a higher parasite 












Hemozoin is quantifiable in RBC and plasma fractions of whole blood in mice. 
 
Fig. 3.6 Heme concentration in negative controls. 
Negative controls purified alongside samples were quantified using luminol to assess 
background heme levels. Average heme concentrations were 0.101 ± 0.016 pmol/ul, 
0.112 ± 0.076 pmol/ul, and <0 pmol/ul in WB, RBC, and plasma negative controls 
respectively. Negative or zero values represent no heme detection in that sample. 
 
To ensure quantification of hemozoin heme and not free heme from the blood 
samples, we developed and processed representative negative controls alongside each 
batch of samples. Fig. 3.6 shows the calculated heme concentrations of individual 
negative controls processed with whole blood, RBC, and plasma samples and quantified 
using luminol. The plasma negative controls showed no quantifiable heme after 
purification. WB negative controls had 0.1 ± 0.016 pmol/ul heme after purification. 
Packed RBC negative controls had 0.1 ± 0.076 pmol/ul heme. Although the mean 
concentrations of heme between WB and packed RBCs is the same, we saw a larger 
deviation between biological replicates of RBC negative controls. As a result, a higher 
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background luminescence was subtracted from RBC samples before calculating their 
hemozoin concentration. 
 
Fig. 3.7 Hemozoin quantified in WB, RBC, and plasma fractions in mice. 
Mean values of hemozoin concentration in WB as well as RBC and plasma fractions are 
plotted over clearance of infection in days post treatment. Individual concentrations were 
calculated by subtracting out background luminescence from the average negative 
control. N of samples positively quantified on each day can be found in Table 3.3. Error 
bars depict SEM.  
 
Of the 120 whole blood samples processed, 91 samples were quantifiable above 
negative control background for hemozoin using the luminol assay. Positive quantifiable 
samples were determined by subtracting out average background luminescence of the 
negative controls from each sample. Only 39 RBC samples were positive for hemozoin 
whereas 60 samples were positive in the plasma. Table 3.3 presents a distribution of the 
positive and negative RBC and plasma samples by each day. As mentioned previously, 
negative controls for RBC samples had a higher concentration of residual heme after 
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purification. However, samples with lower concentrations of heme are not attributed to 
higher negative control values. All plasma samples were quantifiable up until day 4 
whereas a fewer number of RBC samples were positive for those same days. At day 7 
and later, a similar number of samples were quantifiable for each fraction. 
Table 3.3 Distribution of positive and negative samples among all mouse RBC and 
plasma samples quantified. 
Samples positive for hemozoin were able to be quantified above the negative control 
background. Samples below this threshold were considered negative for hemozoin or 
unquantifiable. Depicted in this table is the distribution of the number of individual 
positive and negative samples among RBC and plasma fractions in which hemozoin was 
quantified. 
 
Fig. 3.7 presents mean hemozoin concentrations in WB, RBC, and plasma 
samples for each day post treatment. At days 0, 1, and 2 post treatment, there is a 
significantly higher amount of hemozoin in the RBC fraction as compared to plasma. 
Only 1 RBC sample was positive at day 4, therefore we do not know the significance of 
this concentration. Between days 4 and 10, there is an increase in both RBC and plasma 
concentrations, which is also reflected in the whole blood. At day 13, we see more 
hemozoin in the plasma than the RBC fraction. At day 100, hemozoin concentration 
increases to above plasma concentrations. However, there is only 1 sample that was 
positive for hemozoin in the RBC and plasma fractions at day 100, and no positive 
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samples at days 25 and 86, so the significance of these concentrations is unknown. 
Hemozoin concentrations for matched RBC and plasma samples can be found in Table 
3.4. 
Table 3.4 Hemozoin concentration in RBC and plasma of matched positive mouse 
samples. 
Positive samples were able to be quantified above negative control background. Matched 




Hemozoin is quantifiable in RBC and plasma fractions of infected human whole 
blood. 
Table 3.5 Hemozoin concentration in RBC and plasma fraction of infected human 
patient whole blood. 
Patient RBC and plasma samples positively quantified for hemozoin are presented in 
pmol/ml. Information on days post treatment when the whole blood sample was collected 
and parasitemia by qPCR was only available for the P. falciparum infections. 
 
We purified and quantified hemozoin in the RBC and plasma fractions of 18 
human patient whole blood samples collected at different time points post treatment 
(days0-6) for a total of 45 paired samples. Of the 45 paired samples, hemozoin was 
quantifiable in both fractions of 17 samples among 10 patients. 19 samples were positive 
in the RBC fraction and 33 samples were positive in the plasma fraction. Negative RBC 
and plasma samples varied from patient to patient and did not correlate with days post 
treatment or parasitemia. Quantifiable hemozoin concentrations in RBC and plasma 
fractions of infected patient whole blood can be found in Table 3.5. Day post treatment 
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and parasitemia by qPCR data were only available for the P. falciparum infections. In the 
positive samples, hemozoin is consistently more concentrated in the RBC fraction as 
compared to plasma in all but 1 pair of samples. However, more plasma samples were 
able to be positively quantified over the negative controls as compared to the RBC 
samples. There are no consistent trends in the magnitude of difference between RBC and 
plasma concentrations. 
 
Fig. 3.8 Hemozoin concentrations in patients and mice over first week of clearance. 
Mean hemozoin concentration in RBC and plasma fractions of P. falciparum infected 
patients are plotted as the solid red and blue lines, respectively. Mean hemozoin 
concentration in RBC and plasma of P. berghei infected mice over the same range of 
days post treatment are plotted as the dashed red and blue lines, respectively. Error bars 
depict SEM. 
 
RBC and plasma concentrations over the first week of clearance in patients and 
mice are compared in Fig. 3.8. Between days 0 and 2, RBC concentrations of hemozoin 
are consistently higher than plasma in both patients and mice. In patients, RBC 
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concentrations remain higher out to day 6 post treatment. However, for the patient data, 
we only have 1 pair of samples in which hemozoin was quantifiable for most time points. 
Time points with error bars (SEM) have a maximum N of 3 samples. The ratio between 




In order to explore the compartmental kinetics of hemozoin during clearance of 
infection we sought to develop a sensitive luminescence assay to quantify very small 
amounts of hemozoin. By de-crystallizing hemozoin in NaOH, we can exploit the 
inherent reaction between heme and H2O2 combined with luminol to detect fmol to pmol 
amounts of heme. We demonstrated this by developing a standard curve on the luminol 
assay using hemin in which our lower limit of quantification was 400 fmol heme in a 
volume of 200 ul. This was a 1000-fold increase in sensitivity as compared to measuring 
absorbance at 405 nm on a spectrophotometer. In an equivalent volume on the 
spectrophotometer, the limit of quantification was 600 pmol. The 96-well plate format of 
the luminol assay allows for sensitive quantification of hemozoin in volumes less than 
200ul in a high-throughput format. With a strong imaging system, luminescence from 
each well can be precisely captured and converted to the number of photons emitted per 
second. Because the luminol reaction occurs rapidly after the addition of H2O2, it is 
necessary to minimize the amount of time between this step and imaging. However, a 
time course analysis shows that luminescence degrades over time; therefore, a 1 second 
exposure captures the peak of the reaction. With this fast, high-throughput luminol assay, 
we were able to quantify purified hemozoin from blood samples which were undetectable 
by optical density. 
We used P. berghei infected white mice to model clearance of infection after a 
curative dose of pyronaridine at peak parasitemia. At days 0, 1, 2, 4, 7, 10, 13, 25, 86, and 
100 post treatment, we harvested whole blood, livers, and spleens to purify and quantify 
hemozoin. In previous studies, hemozoin concentration in mouse livers and spleens 
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rapidly increased during infection [4]. In a long term study analyzing hemozoin during 
clearance of infection, hemozoin appeared to move from the liver to the spleen [5]. We 
observed a rapid decline in liver concentration (normalized to tissue weight) along with a 
rapid increase in spleen concentration (also normalized) between days 4 and 7 post 
treatment. Where during the first week of clearance, hemozoin concentration is 
significantly higher in the liver, after day 7, it is significantly higher in the spleen. When 
looking at total hemozoin content, there is more hemozoin in the liver until day 10 post 
treatment as compared to the spleen. Where we see a switch in liver and spleen 
concentrations when normalized to tissue size, we do not see this reflected in total 
hemozoin content. It appears that around day 13, the total amount of hemozoin present in 
the spleen is the same as that of the liver. Studies have shown hemozoin to persist in 
tissue as far as 9 months post clearance which we were also able to demonstrate with 
quantifiable amounts of hemozoin in the liver and spleen at day 100 post clearance.  
In whole blood, we expect to see the greatest amount of hemozoin at day 0 
because the mice have reached a peak parasitemia of infection. The curative dose of 
pyronaridine at day 0 is reflected in the rapid decline of hemozoin concentration between 
days 0-4 as parasite numbers are drastically reduced due to drug treatment. Around the 
same time we see a switch between liver and spleen concentrations, we see a rapid 
increase of hemozoin in whole blood. This may represent clearance of parasites from the 
liver to the spleen via the whole blood. Parasite clearance from blood occurs at day 6 by 
qPCR. Therefore, an increase in spleen concentration around this time may correspond to 
clearance of parasites in the blood through the spleen. The peak at day 10 in whole blood 
also corresponds to the decrease in total hemozoin content in the liver and lower levels in 
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the spleen. Therefore, we assume that most of the hemozoin is in the blood at this time 
point. As clearance continues through to day 13, hemozoin levels decline in the whole 
blood, liver and spleen. Hemozoin concentrations in the spleen after day 13 are 
represented with an N of at least 10 mice, therefore, we are confident in these values. 
However, we only processed livers from 3-5 mice for each group and would need to 
process more to confirm our current values for hemozoin concentration in the liver. We 
would also like to see whether the unexpected increase at day 86 is an artifact or caused 
by a recurrence of parasitemia.  
In the study by Pisciotta et. al., hemozoin was not detected in up to 320 ul of 
plasma from mouse whole blood [7]. However, with our sensitive luminol assay, we were 
able to quantify hemozoin in both RBC and plasma fractions of whole blood from 
Plasmodium infected mice and human patients. In mice, we see rapid clearance of 
hemozoin from the RBC fraction, synchronous to whole blood. Although the trends are 
similar between WB and RBC hemozoin concentrations at days 0-2, a higher RBC 
concentration may reflect that we purified hemozoin from packed RBCs resulting in a 
higher hematocrit comparatively to WB. At days 0-2, there is significantly higher 
amounts of hemozoin in the RBC fraction as compared to plasma. This may represent the 
large numbers of trophozoite-infected RBCs being cleared from the whole blood 
immediately after drug treatment. Between days 7-13, however, we do not see a 
significant difference in the RBC and plasma levels of hemozoin. However, a higher 
percentage of plasma samples were able to be positively quantified at days 7-13 than 
RBC samples. This may indicate a shift towards hemozoin remaining in the plasma 
considering the unwashed RBC pellet may also account for hemozoin-containing WBCs. 
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Long term hemozoin concentrations in these fractions cannot be determined by 
our analysis because we only had 1 positive sample in both fractions at day 100. 
Therefore, we would need to perform more long term mouse experiments to determine if 
there is residual hemozoin in the plasma after RBC clearance post day 13. Calculation of 
the ratio of hemozoin in RBC to plasma fractions resulted in a range of 2-fold to 20,000-
fold and does not remain consistent over the course of clearance nor within a group of 
mice on a single day.  
The implication of this research is to understand hemozoin kinetics in humans. 
Therefore, we looked at hemozoin concentrations within the washed RBC and plasma 
fractions of patients infected with Plasmodium. Although limited in the number of 
samples and duration post treatment, we saw more hemozoin in the RBC fraction in all 
but one of the samples. This reflects what was observed in the mice, where more 
hemozoin was present in the RBC fraction of mouse samples. Because we only had 1-3 
patient samples per time point, it is difficult to say whether the trends seen during 
clearance of infection in humans are of any biological significance. However, we did 
observe a rapid decline of hemozoin concentration up to 2 days post treatment as 
parasites are being cleared from the blood, similar to what occurred in the mice.   
We were able to quantify hemozoin in fewer patient samples as compared to mice 
relative to the total number of samples processed. This may be due to the limitations of 
human blood collection. Mouse blood was taken via cardiac puncture, and therefore 
yielded dispensable volumes for us to work with. The human samples were from 
peripheral blood which generally have lower amounts of trophozoites due to their nature 
of sequestration. Therefore, it is possible that we were quantifying hemozoin production 
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from ring stage parasites but were not accurately capturing total hemozoin concentration 
due to the limited number of circulating trophozoites in peripheral blood. This can be 
confirmed by comparing hemozoin concentrations to the specific life cycle stages of 
Plasmodium in our patient samples. Because our patient RBC pellets were washed, we 
theoretically removed any hemozoin containing WBCs, giving us a more accurate 
measure of RBC hemozoin content. We would like to continue to process more patient 
samples, preferably at consistent time points during the first two weeks of clearance to 
replicate the kinetics we see in mice. With a sensitive luminescence assay, we can 
continue to quantify hemozoin in Plasmodium infect patients to truly determine the 
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